RBC Bioscience Corporation (TPEX:6848)

RBC Bioscience Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	43.18	36.44	79.86	65.18	75.93	97.47
Cash & Short-Term Investments	43.18	36.44	79.86	65.18	75.93	97.47
Cash Growth	-29.19%	-54.37%	22.53%	-14.16%	-22.10%	-21.36%
Accounts Receivable	29.31	26.21	13.49	23	25.59	24.68
Other Receivables	2.23	1.02	1.27	0.7	0.71	1.33
Receivables	31.54	27.23	14.76	23.7	26.3	26.01
Inventory	48.18	47.49	52.76	44.42	47.2	51.2
Other Current Assets	10.36	9.1	9.43	6.91	7.47	33.95
Total Current Assets	133.26	120.26	156.8	140.21	156.9	208.62
Property, Plant & Equipment	503.15	508.55	520.97	533.54	556.74	621.22
Other Intangible Assets	15.79	17.18	12.87	3.14	2.45	3.17
Long-Term Deferred Tax Assets	3.18	3.18	3.53	3.26	3.41	4.09
Other Long-Term Assets	70.53	75.33	69.71	73.63	71.05	10.51
Total Assets	725.9	724.49	763.88	753.79	790.55	847.6

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	22.71	24.07	23.77	15.72	22.71	35.75
Accrued Expenses	4.94	13.86	13.04	-	-	-
Short-Term Debt	15	-	25	35	40	64.65
Current Portion of Long-Term Debt	-	33.34	27.92	23.03	22.69	2.11
Current Portion of Leases	0.69	1.01	1.13	1.02	1.77	1.98
Current Income Taxes Payable	-	5.13	4.92	1.26	8.51	8.05
Current Unearned Revenue	0.51	0.71	0.92	0.31	0.26	1.34
Other Current Liabilities	79.07	18.09	14.91	23.43	27.8	34.2
Total Current Liabilities	122.91	96.2	111.6	99.77	123.74	148.07
Long-Term Debt	339.52	356.37	399.8	412.33	416.63	439.82
Long-Term Leases	0.17	0.46	0.85	0.27	0.66	2.43
Long-Term Unearned Revenue	1.23	0.94	0.61	0.43	0.43	0.45
Pension & Post-Retirement Benefits	1.7	1.7	1.44	-	-	-
Other Long-Term Liabilities	0.29	0.29	0.29	0.29	0.29	-
Total Liabilities	465.81	455.96	514.58	513.08	541.73	590.77

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	142.73	142.73	129.76	129.76	129.76	117.96
Additional Paid-In Capital	50.45	50.45	50.45	50.45	50.45	50.45
Retained Earnings	66.91	75.36	69.09	60.5	68.61	88.42
Shareholders' Equity	260.09	268.54	249.3	240.71	248.81	256.83
Total Liabilities & Equity	725.9	724.49	763.88	753.79	790.55	847.6

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	355.37	391.17	454.7	471.65	481.75	510.99
Net Cash (Debt)	-312.19	-354.73	-374.84	-406.47	-405.82	-413.52
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-21.77	-24.66	-26.11	-28.42	-28.35	-30.57
Filing Date Shares Outstanding	14.24	14.27	14.27	14.27	14.27	14.27
Total Common Shares Outstanding	14.24	14.27	14.27	14.27	14.27	14.27
Working Capital	10.34	24.06	45.2	40.45	33.16	60.55
Book Value Per Share	18.27	18.81	17.47	16.86	17.43	17.99
Tangible Book Value	244.31	251.36	236.43	237.57	246.36	253.66
Tangible Book Value Per Share	17.16	17.61	16.56	16.64	17.26	17.77
Land	-	354.26	354.26	354.26	354.26	401.43
Buildings	-	168.6	170.11	170.11	183.13	193.16
Machinery	-	78.09	76.3	75.96	69.14	60.79

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 19, 2026

Data Sources Report a data error